Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting

• Main Authors: Stuart A. Ostby, Haller J. Smith, Charles A. Leath, III
• Format: Article
• Language: English
• Published: Elsevier 2019-08-01
• Series: Gynecologic Oncology Reports
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352578919300670

Poly-ADP ribose polymerase inhibitors (PARPi) are a promising new treatment option for patients with ovarian cancer and are moderately emetogenic. Tolerance of therapy is paramount, and uncontrolled nausea and vomiting may limit use. Although most patients will experience improvement in nausea and vomiting after one to two months, approximately one in twenty patients will discontinue therapy due to unrelieved symptom burden.Three cases of olaparib-related nausea and vomiting mitigated by primary pyridoxine use are reported. Case 1 demonstrates successful use of pyridoxine in breakthrough nausea. Case 2 details the use of pyridoxine following refractory nausea and vomiting requiring hospitalization. Case 3 describes a prophylactic approach for a patient with significant anticipatory nausea. All three patients tolerated olaparib after starting and continuing pyridoxine. Vitamin B6, or pyridoxine, was successful as both a therapeutic and prophylactic option for significant treatment-related nausea and vomiting with PARPi use. Keywords: PARP inhibitor, Gastrointestinal side effects, Pyridoxine